New hope for stomach cancer: experimental combo aims to wipe out tumors before surgery
NCT ID NCT07477444
Summary
This study is testing whether adding two new drugs (zanidatamab and tislelizumab) to standard chemotherapy before surgery is safe and more effective for people with HER2-positive stomach or esophageal cancer. The goal is to completely eliminate cancer cells in the tissue removed during surgery, which could lead to better long-term outcomes. The trial will enroll 29 patients with localized, operable cancer to first check safety and then measure how many patients achieve complete tumor disappearance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.